Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology PATRICK SCHÖFFSKI The Oncologist 2009;14:559–570
A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1-Interacting Properties, in Patients with Advanced Solid Tumors Charles Taylor, Deborah L. Pilkington, et al. Clin Cancer Res 2006;12:5182-5189
HMN-176, an Active Metabolite of the Synthetic Antitumor Agent HMN-214, Restores Chemosensitivity to Multidrug-Resistant Cells by Targeting the Transcription Factor NF-Y Nobuko Ohshima, Mami Ikenoya, et al. Cancer Res 2003;63:6942-6947
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.